TY  - JOUR
AU  - Garassino, Marina Chiara
AU  - Cho, Byoung-Chul
AU  - Kim, Joo-Hang
AU  - Mazières, Julien
AU  - Vansteenkiste, Johan
AU  - Lena, Hervé
AU  - Corral Jaime, Jesus
AU  - Gray, Jhanelle E
AU  - Powderly, John
AU  - Chouaid, Christos
AU  - Bidoli, Paolo
AU  - Wheatley-Price, Paul
AU  - Park, Keunchil
AU  - Soo, Ross A
AU  - Huang, Yifan
AU  - Wadsworth, Catherine
AU  - Dennis, Phillip A
AU  - Rizvi, Naiyer A
AU  - ATLANTIC Investigators
PY  - 2018
DO  - 10.1016/S1470-2045(18)30144-X
UR  - http://hdl.handle.net/10668/12243
T2  - The Lancet. Oncology
AB  - Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-), but clinical benefit in patients...
LA  - en
KW  - 4-Butyrolactone
KW  - Aged
KW  - Anaplastic Lymphoma Kinase
KW  - Antibodies, Monoclonal
KW  - Antineoplastic Agents, Immunological
KW  - Aspartate Aminotransferases
KW  - B7-H1 Antigen
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Diarrhea
KW  - ErbB Receptors
KW  - Fatigue
KW  - Female
KW  - Humans
KW  - Injection Site Reaction
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Pneumonia
KW  - Progression-Free Survival
KW  - Response Evaluation Criteria in Solid Tumors
KW  - gamma-Glutamyltransferase
TI  - Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
TY  - research article
VL  - 19
ER  -